PREVU* life insurance trial
This article was originally published in The Tan Sheet
Executive Summary
A 25,000-patient study evaluating PREVU* LT in the life insurance testing market is expected to begin in the second quarter of 2005, International Medical Innovations announces May 10. The PREPARE study (PREVU Predicts Atherosclerosis Risk & Events) will test life insurance applicants with the product and compare the results to "traditional risk assessment measures," IMI says. PREVU* LT is the lab-processed version of the company's skin sterol test, which measures cholesterol levels by testing skin tissues. Entering the insurance market offers an opportunity to the firm because a "significant number" of the 13.5 mil. individuals who purchased life insurance policies in 2003 did not have a cardiovascular disease assessment, IMI says. The company reached a licensing agreement last year with McNeil's consumer division that includes working to develop an OTC version of the product (1"The Tan Sheet" June 7, 2004, p. 10)...